ReviewDrug delivery2023
Recent advances in drug delivery systems for targeting brain tumors.
Review in Drug delivery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 78 citations in OpenAlex.
- Recent Advances in Lipid Nanoparticle-Mediated Respiratory and Gastrointestinal Mucosal Delivery of Nucleic Acids.Bioengineering (Basel, Switzerland) · 2026Review
- HMGA proteins in the nervous system: role in brain tumorigenesis and neurodegeneration.Cell death discovery · 2026Review
- Mapping the landscape and evolution of drug delivery for glioma: a bibliometric and visual analysis.Discover oncology · 2026Article
- Comparison of Fluorescent Probes for IDH-Wildtype Glioblastoma, Metastatic Brain Tumors, and PCNSL: A Biomechanical Perspective.International journal of molecular sciences · 2026Review
- Evolving Landscape of Glioblastoma Research: Integrating Therapeutic Advances and Diagnostic Frontiers.Brain sciences · 2026Review
- Unraveling the Mysteries of Brain Cancer from Diagnosis to Treatment.Pharmaceutical nanotechnology · 2026Review
- Coencapsulation of doxorubicin and curcumin in liposomes modified with folic acid for reversal of drug resistance in glioma.Frontiers in oncology · 2026Article
- Dynamic tumor microenvironment remodeling in cancer therapy resistance: molecular mechanisms and translational opportunities.Frontiers in cell and developmental biology · 2026Review
- Nanocarrier Strategies in Glioblastoma: Overcoming Barriers to Effective Brain Tumor Therapy.AAPS PharmSciTech · 2025Review
- Construction of dual-targeted liposomes loaded with celastrol and their application in treating intrahepatic cholangiocarcinoma.Materials today. Bio · 2025Article
- Study on the Construction and Anti-Tumor Effect of aPDL1/aMUC1 Double Antibody Modification of Doxorubicin Liposome.ACS omega · 2025Article
- Advancements in nanotheranostics for glioma therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Trojan Horse Delivery Strategies of Natural Medicine Monomers: Challenges and Limitations in Improving Brain Targeting.Pharmaceutics · 2025Review
- Towards a New Dawn for Neuro-Oncology: Nanomedicine at the Service of Drug Delivery for Primary and Secondary Brain Tumours.Brain sciences · 2025Review
- Targeting Brain Drug Delivery with Macromolecules Through Receptor-Mediated Transcytosis.Pharmaceutics · 2025Review
- Hybrid Deep Learning for Brain Tumor Detection: Combining DenseNet and Custom CNN for Enhanced Accuracy.Biomedical engineering and computational biology · 2025Article
- Nuclei-targeted Therapeutic Delivery: A Novel Concept for the Treatment of Cancer.Mini reviews in medicinal chemistry · 2025Article
- Encapsulation of paclitaxel into date palm lipid droplets for enhanced brain cancer therapy.Scientific reports · 2024Article
- Drug Delivery Across the Blood-Brain Barrier: A New Strategy for the Treatment of Neurological Diseases.Pharmaceutics · 2024Review
- Current Combinatorial Therapeutic Aspects: The Future Prospect for Glioblastoma Treatment.Current medical science · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain tumor accounts for about 1.6% of incidence and 2.5% of mortality of all tumors, and the median survival for brain tumor patients is only about 20 months. The treatment for brain tumor still faces many challenges, such as the blood-brain barrier (BBB), blood-brain tumor barrier (BBTB), the overexpressed efflux pumps, the infiltration, invasion, high heterogeneity of tumor cells, drug resistance and immune escape caused by tumor microenvironment (TME) and cancer stem cells (CSC). This review attempts to clarify the challenges for multi-functional nano drug delivery systems (NDDS) to cross the BBB and target the cancer cells or organelles, and also provides a brief description of the different types of targeted multi-functional NDDS that have shown potential for success in delivering drugs to the brain. Further, this review also summarizes the research progress of multi-functional NDDS in the combination therapy of brain tumors from the following sections, the combination of chemotherapy drugs, chemotherapy-chemodynamic combination therapy, chemotherapy-immunization combination therapy, and chemotherapy-gene combination therapy. We also provide an insight into the recent advances in designing multi-functional NDDS for combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.